Fosaprepitant Dimeglumine for Injection 150 mg
APRELIEVA 150 MG (Fosaprepitant Dimeglumine for Injection 150 mg) is a prescription antiemetic medicine used to prevent chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV). It contains Fosaprepitant Dimeglumine 150 mg, a prodrug that is rapidly converted into aprepitant in the body. The medicine works by blocking neurokinin-1 (NK1) receptors in the brain, helping prevent nausea and vomiting associated with cancer treatment and surgical procedures.
Nausea and vomiting are among the most common and distressing side effects experienced by patients undergoing chemotherapy. These symptoms can significantly affect quality of life, nutritional intake, treatment adherence, and overall recovery. APRELIEVA 150 MG is specifically designed to help reduce the occurrence and severity of these symptoms, enabling patients to continue their treatment with greater comfort and confidence.
Unlike traditional antiemetic medicines that primarily target serotonin pathways, Fosaprepitant works on the substance P/NK1 receptor pathway, providing additional protection against delayed nausea and vomiting that may occur several hours or days after chemotherapy.
APRELIEVA 150 MG is commonly used in:
• Chemotherapy-Induced Nausea and Vomiting (CINV)
• Highly Emetogenic Chemotherapy Regimens
• Moderately Emetogenic Chemotherapy Regimens
• Postoperative Nausea and Vomiting (PONV)
• Supportive Cancer Care Programs
• Oncology Treatment Protocols
• Hospital and Specialty Care Settings
The medicine is often administered as part of a combination antiemetic regimen alongside other medicines such as serotonin receptor antagonists and corticosteroids to provide comprehensive nausea and vomiting prevention.
Manufactured under strict pharmaceutical quality standards, APRELIEVA 150 MG is designed to provide reliable therapeutic performance, safety, and consistency. The injection should only be administered by qualified healthcare professionals in hospitals, oncology centers, or specialized treatment facilities.
Patients receiving Fosaprepitant therapy may require monitoring for infusion-related reactions, allergic responses, and overall treatment tolerance. Healthcare providers carefully evaluate patient needs to ensure optimal supportive care during chemotherapy or surgery.
Due to its effectiveness in preventing chemotherapy-related nausea and vomiting, APRELIEVA 150 MG has become an important component of modern oncology supportive care programs worldwide.
View Details
Topotecan Injection IP 2.5mg
HYCALIEVA 2.5 MG (Topotecan Injection IP 2.5 mg) is a prescription anticancer medicine used for the treatment of specific types of cancer, including ovarian cancer, small cell lung cancer (SCLC), and cervical cancer. It contains Topotecan 2.5 mg, a potent chemotherapy agent belonging to the class of medicines known as topoisomerase I inhibitors. The medicine works by interfering with the DNA replication process in cancer cells, helping to slow tumor growth and prevent the spread of cancer.
Cancer develops when abnormal cells multiply uncontrollably. These rapidly dividing cells require continuous DNA replication to survive and spread. Topotecan blocks an enzyme called topoisomerase I, which plays a critical role in DNA repair and replication. By inhibiting this enzyme, HYCALIEVA 2.5 MG causes damage to cancer cell DNA, leading to cell death and reduced tumor progression.
Topotecan is widely used in oncology treatment programs and may be prescribed when certain cancers recur, progress after previous treatment, or require additional chemotherapy support. It is commonly administered in hospitals, cancer centers, and specialized oncology facilities under the supervision of trained healthcare professionals.
HYCALIEVA 2.5 MG is commonly prescribed for:
• Ovarian Cancer
• Recurrent Ovarian Cancer
• Small Cell Lung Cancer (SCLC)
• Relapsed Small Cell Lung Cancer
• Advanced Cervical Cancer
• Metastatic Cancer Management
• Combination Chemotherapy Protocols
• Oncology Treatment Programs
The medicine may be used alone or in combination with other anticancer agents depending on the type of cancer, stage of disease, and individual treatment goals.
Manufactured under strict pharmaceutical quality standards, HYCALIEVA 2.5 MG is designed to provide reliable therapeutic performance, safety, and consistency. The injection should only be administered by qualified healthcare professionals experienced in chemotherapy and cancer care.
Patients receiving Topotecan therapy typically require routine blood tests, liver and kidney function monitoring, and regular medical assessments to evaluate treatment response and manage potential side effects.
Due to its established role in cancer treatment, HYCALIEVA 2.5 MG remains an important component of modern oncology care and chemotherapy protocols.
View Details
Doxorubicin Hydrochloride iInjection IP 50mg
DOXLIEVA 50 mg contains Doxorubicin Hydrochloride, an anthracycline antitumor antibiotic. It acts by intercalating into DNA, inhibiting topoisomerase II, and generating free radicals, leading to DNA damage and apoptosis of cancer cells. It is a backbone drug in many chemotherapy regimens.
View Details
Azacitidine for Injection 100MG
AZALIEVA 100 mg contains Azacitidine, a hypomethylating agent and pyrimidine nucleoside analogue. It incorporates into DNA and RNA, leading to inhibition of DNA methyltransferase, reactivation of tumor suppressor genes, and normalization of bone marrow function. It is mainly used in myelodysplastic syndromes (MDS).
View Details
Dactinomycin for Injection USP 0.5MG
DACTOLIEVA 0.5 mg contains Dactinomycin (Actinomycin D), an antitumor antibiotic. It works by intercalating into DNA, thereby inhibiting RNA synthesis and blocking protein production, leading to cancer cell death. It is especially effective in pediatric and germ cell tumors.
View Details
Plerixafor Injection 24mg
MOZOLIEVA 24 mg contains Plerixafor, a hematopoietic stem cell mobilizer. It is a CXCR4 chemokine receptor antagonist that disrupts the interaction between CXCR4 and SDF-1α, causing rapid release of CD34+ stem cells from the bone marrow into peripheral blood for collection.
View Details
Vinorelbine Injection IP 50mg
NAVELIEVA 50 mg contains Vinorelbine, a semi-synthetic vinca alkaloid. It inhibits microtubule assembly by binding to tubulin, thereby arresting cell division in the M phase of the cell cycle. It is primarily used in lung and breast cancers.
View Details
Fludarabine Phosphate for Injection 50mg
FLULIEVA 50 mg contains Fludarabine Phosphate, a purine nucleoside analogue antimetabolite. It is intracellularly converted to fludarabine triphosphate, which inhibits DNA polymerase, ribonucleotide reductase, and DNA primase, leading to suppression of DNA synthesis and apoptosis. It is widely used in hematologic malignancies.
View Details
Fludarabine Phosphate for Injection 10mg
FLULIEVA 10 mg contains Fludarabine Phosphate, a purine nucleoside analogue antimetabolite. Inside the cell, it is converted to the active metabolite fludarabine triphosphate, which inhibits DNA polymerase, ribonucleotide reductase, and DNA primase, leading to inhibition of DNA synthesis and apoptosis. It is primarily used in hematological malignancies.
View Details
L-Asparaginase Injection 5000IU
L-GANASELIEVA 5,000 IU contains L-Asparaginase, an antineoplastic enzyme used mainly in leukemia treatment. It works by depleting the amino acid asparagine from the blood. Leukemic lymphoblasts cannot synthesize asparagine on their own, so depletion leads to inhibition of protein synthesis and cell death.
View Details
L-Asparaginase Injection 10000IU
L-GANASELIEVA 10,000 IU contains L-Asparaginase, an antineoplastic enzyme. It works by depleting asparagine, an amino acid essential for leukemic lymphoblasts. Normal cells can synthesize asparagine, but leukemic cells cannot—leading to selective tumor cell death.
View Details
Methotrexate Injection 500mg
TREXLIEVA 500 mg contains Methotrexate, an antimetabolite and antifolate chemotherapeutic agent. It inhibits dihydrofolate reductase (DHFR), blocking folate metabolism and DNA synthesis in rapidly dividing cells. This strength is commonly used in high-dose methotrexate (HD-MTX) oncology protocols.
View Details
